<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">Ribavirin, a guanosine analog prescribed for viral hemorrhagic fever and respiratory syncytial virus, inhibits viral RNA polymerase and mRNA capping. It has no in-vitro activity against SARS 
 <xref rid="b0250" ref-type="bibr">[50]</xref>, and is far less potent against SARS-CoV-2 in-vitro than antivirals like Remdesivir 
 <xref rid="b0170" ref-type="bibr">[34]</xref>. It is associated with hemolytic anemia which could lead to exacerbation of cardiac disease in co-morbid patients. Further, it is also known to be teratogenic.
</p>
